Medication Monitor

Generic Name (Trade Name—Company)
August 9, 2011


First solution formulation approved


Treatment of numerous cancers including ovarian, non-small cell lung cancer, breast, and pancreatic cancer

Hospira announced the FDA approval of the first solution formulation of gemcitabine injection. The product, which launches in early September, will be marketed in vials that contain 200 mg, 1 g, and 2 g of drug (concentration 38 mg/mL). Previously, Hospira launched lyphophilized, or freeze-dried, preparations of the product in the same strengths.

This new formulation eliminates the need for reconstitution.